Osteoarthritis Market (Hand, Knee & Hip OA) 2024 Forecasts for 7 Major Markets

24 Feb, 2016, 21:00 ET from ReportsnReports

PUNE, India, February 25, 2016 /PRNewswire/ --

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2024 is a market research study that provides an overview of the risk factors, comorbidities, and the global and historical trends for hand OA, knee OA, and hip OA in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of hand OA, knee OA, and hip OA segmented by age and sex in these markets and is written and developed by Masters- and PhD-level epidemiologists.

Complete report on Osteoarthritis - Epidemiology Forecast to 2024 spread across 82 pages, supported with 29 tables and 18 figures is now available at http://www.reportsnreports.com/reports/443599-epicast-report-osteoarthritis-epidemiology-forecast-to-2024.html .

Epidemiologists forecast an increase in the total prevalent cases of hand OA in the 7MM from 151,439,533150,635,612 total prevalent cases in 2014 to 176,143,154175,213,683 total prevalent cases in 2024 at an AGR of 1.63% during the forecast period. Epidemiologists forecast that the total prevalent cases of knee OA in the 7MM are expected to increase from 110,840,501 total prevalent cases in 2014 to 127,929,359 total prevalent cases in 2024 at an AGR of 1.54% during the forecast period. Epidemiologists forecast that the total prevalent cases of hip OA in the 7MM are expected to increase from 61,150,916 total prevalent cases in 2014 to 69,699,696 total prevalent cases in 2024 at an AGR of 1.4% during the forecast period.

The diagnosed prevalent cases of hand OA in the 7MM are expected to increase from 61,045,59060,125,229 diagnosed prevalent cases in 2014 to 70,996,37570,072,690 diagnosed prevalent cases in 2024 at an AGR of 1.635% during the forecast period. The diagnosed prevalent cases of knee OA in the 7MM are expected to increase from 37,845,305 diagnosed prevalent cases in 2014 to 43,877,213 diagnosed prevalent cases in 2024 at an AGR of 1.59% during the forecast period. The diagnosed prevalent cases of hip OA in the 7MM are expected to increase from 15,116,094 diagnosed prevalent cases in 2014 to 17,276,030 diagnosed prevalent cases in 2024 at an AGR of 1.43% during the forecast period.

Order a copy of EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2024 market research report at http://www.reportsnreports.com/Purchase.aspx?name=443599 .

OA is a degenerative disease of the entire joint, which involves the cartilage, joint lining, ligaments, and underlying bone. OA is the most common form of joint disease. The most affected joints are the knee, hip, hand, and spine. The disease's onset is gradual and typically seen in middle-aged to elderly people. OA is characterized by pain, stiffness, swelling, crepitus, and limited movement of the affected joint. OA will be the fourth leading cause of disability by the year 2020.

Reasons to buy 

The OA EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global OA market.
  • Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OA therapeutics in each of the markets covered.

Another newly published market research titled Rheumatoid Arthritis - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects. Complete report on Rheumatoid Arthritis Pipeline Review market research report of 66 pages is available at http://www.reportsnreports.com/reports/468289-rheumatoid-arthritis-pipeline-review-h2-2015.html .

Explore more reports on pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml


SOURCE ReportsnReports